scholarly article | Q13442814 |
review article | Q7318358 |
P356 | DOI | 10.1016/S0140-6736(10)60962-2 |
P698 | PubMed publication ID | 21131039 |
P50 | author | Frits Rosendaal | Q16319080 |
P2093 | author name string | Sabine Eichinger | |
Paul Alexander Kyrle | |||
P2860 | cites work | High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study | Q81743014 |
Overweight, obesity, and the risk of recurrent venous thromboembolism | Q81769586 | ||
Recurrence rate after a first venous thrombosis in patients with familial thrombophilia | Q81885362 | ||
Family history for venous thromboembolism and the risk for recurrence | Q82345821 | ||
The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism | Q82769283 | ||
Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time | Q83193158 | ||
Thrombophilia testing for prevention of recurrent venous thromboembolism | Q24241821 | ||
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer | Q28186303 | ||
The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies | Q28237512 | ||
Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review | Q33468803 | ||
Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran | Q33973559 | ||
Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study | Q33988556 | ||
Clinical guidelines for testing for heritable thrombophilia | Q34096556 | ||
Antithrombotic therapy for venous thromboembolic disease | Q34131105 | ||
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism | Q34179254 | ||
Genetic susceptibility to venous thrombosis | Q34223106 | ||
Thrombophilia, clinical factors, and recurrent venous thrombotic events | Q34419598 | ||
D-dimer testing to determine the duration of anticoagulation therapy | Q34576728 | ||
Risk of major hemorrhage for outpatients treated with warfarin | Q34751905 | ||
Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review | Q36445071 | ||
Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. | Q36550717 | ||
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy | Q36841584 | ||
A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies | Q37020336 | ||
Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism | Q37288236 | ||
Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism | Q37741638 | ||
Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous Thrombosis | Q41099975 | ||
A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. | Q41746170 | ||
Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism | Q43556960 | ||
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. | Q43597590 | ||
Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. | Q44196663 | ||
Extended oral anticoagulant therapy after a first episode of pulmonary embolism. | Q44496670 | ||
Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism | Q44680678 | ||
Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor | Q44852505 | ||
Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children | Q45050847 | ||
The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism | Q45298422 | ||
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism | Q45877633 | ||
Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism. | Q46014301 | ||
Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. | Q46123639 | ||
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial | Q46368145 | ||
Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism | Q47247982 | ||
The risk of recurrent venous thromboembolism in men and women | Q47332296 | ||
Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis | Q47351547 | ||
High plasma levels of factor VIII and risk of recurrence of venous thromboembolism | Q48036239 | ||
Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. | Q50780747 | ||
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. | Q50782352 | ||
High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. | Q51127047 | ||
Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. | Q51574600 | ||
Age at first venous thromboembolism and risk of recurrence: a prospective cohort study. | Q51603817 | ||
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. | Q51831890 | ||
New diagnostic strategies for pulmonary embolism. | Q51888146 | ||
A prediction rule to identify low-risk patients with pulmonary embolism. | Q51922063 | ||
Comparison of the clinical history of symptomatic isolated distal deep-vein thrombosis vs. proximal deep vein thrombosis in 11 086 patients. | Q53186557 | ||
Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. | Q53354829 | ||
The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. | Q53361537 | ||
A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. | Q53374794 | ||
Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial | Q56786477 | ||
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study | Q56989286 | ||
Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia | Q57003501 | ||
The Risk of Recurrent Venous Thromboembolism in Patients with an Arg506→Gln Mutation in the Gene for Factor V (Factor V Leiden) | Q61657715 | ||
Long-term outcomes of deep-vein thrombosis | Q72231512 | ||
The management of thrombosis in the antiphospholipid-antibody syndrome | Q72619159 | ||
A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial | Q73180786 | ||
Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors | Q73592975 | ||
The risk of recurrent venous thromboembolism among patients with high factor IX levels | Q73691028 | ||
Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study | Q73836575 | ||
D-dimer levels and risk of recurrent venous thromboembolism | Q73864376 | ||
High plasma levels of factor VIII and the risk of recurrent venous thromboembolism | Q74197149 | ||
Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism | Q78670334 | ||
Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer | Q79696092 | ||
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients | Q79765195 | ||
Pulmonary embolism | Q79954098 | ||
Incidence and mortality of venous thrombosis: a population-based study | Q79969827 | ||
High-density lipoprotein and the risk of recurrent venous thromboembolism | Q79985834 | ||
Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation | Q79989153 | ||
Homozygosity in the single nucleotide polymorphism Ser128Arg in the E-selectin gene associated with recurrent venous thromboembolism | Q80111833 | ||
Genetic variation in heme oxygenase 1 (HMOX1) and the risk of recurrent venous thromboembolism | Q80507637 | ||
Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study | Q81322442 | ||
Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis | Q81425221 | ||
Deep vein thrombosis | Q81584045 | ||
The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease | Q81636022 | ||
P433 | issue | 9757 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | thrombosis | Q261327 |
P304 | page(s) | 2032-2039 | |
P577 | publication date | 2010-12-03 | |
P1433 | published in | The Lancet | Q939416 |
P1476 | title | Risk assessment for recurrent venous thrombosis. | |
P478 | volume | 376 |
Q34436061 | 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism |
Q41874126 | A case of pulmonary thromboembolism due to coagulation factor V Leiden in Japan ~ usefulness of next generation sequencing~. |
Q37368820 | A systematic review of the utility of residual vein obstruction studies in primary and secondary venous thrombosis |
Q26776112 | Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art |
Q26783455 | Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review |
Q33841714 | Association between TLR9 rs5743836 polymorphism and risk of recurrent venous thromboembolism |
Q53741293 | CDC Grand Rounds: preventing hospital-associated venous thromboembolism. |
Q38808401 | Cardiovascular fitness in young males and risk of unprovoked venous thromboembolism in adulthood |
Q60949185 | Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome |
Q43703844 | Clinical presentation of venous thromboembolism in inflammatory bowel disease |
Q47129005 | Combined Thrombophilia in a Young Male Presenting as Life Threatening Pulmonary Embolism |
Q58108078 | Cost-effectiveness of alternative anticoagulation strategies for postoperative management of total knee arthroplasty patients |
Q64936707 | Current and future burden of venous thrombosis: Not simply predictable. |
Q37648653 | D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. |
Q38777416 | Economic evaluation of strategies for restarting anticoagulation therapy after a first event of unprovoked venous thromboembolism. |
Q47828398 | Effects of magnesium sulphate on coagulation after laparoscopic colorectal cancer surgery, measured by rotational thromboelastometry (ROTEM® ). |
Q55252767 | Elevated leptin and decreased adiponectin independently predict the post-thrombotic syndrome in obese and non-obese patients. |
Q37370722 | Epidemiology of recurrent venous thrombosis |
Q41667853 | Epidemiology of venous thromboembolism |
Q89002090 | Epidemiology, Pathophysiology, and Natural History of Pulmonary Embolism |
Q37874154 | Estrogen and thrombosis: controversies and common sense |
Q45870309 | External validation of the DASH prediction rule: a retrospective cohort study. |
Q43468383 | Family history of venous thromboembolism (VTE) and risk of recurrent hospitalization for VTE: a nationwide family study in Sweden |
Q47554769 | Fat mass and obesity-associated gene rs9939609 polymorphism is a potential biomarker of recurrent venous thromboembolism in male but not in female patients |
Q35153652 | HIV-Associated Venous Thromboembolism |
Q34305696 | Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study |
Q40596897 | Hospital-related first venous thromboembolism and risk of recurrence |
Q51220285 | Identification of Genetic Aberrations in Thrombomodulin Gene in Patients With Recurrent Venous Thromboembolism. |
Q35890411 | Impact of Inherited Prothrombotic Disorders on the Long-Term Clinical Outcome of Percutaneous Transluminal Angioplasty in Patients with Diabetes. |
Q44446974 | Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. |
Q36589493 | Inherited genetic markers for thrombophilia in northeastern Iran (a clinical-based report). |
Q38992105 | Lipid levels and risk of recurrent venous thrombosis: results from the MEGA follow-up study. |
Q47728750 | Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists. |
Q26749273 | Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis |
Q36718482 | Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach |
Q26830769 | Managing pulmonary embolism using prognostic models: future concepts for primary care |
Q35948292 | Medical management of venous thromboembolism: what the interventional radiologist needs to know |
Q89529700 | Oral Intake of EPA:DHA 6:1 by Middle-Aged Rats for One Week Improves Age-Related Endothelial Dysfunction in Both the Femoral Artery and Vein: Role of Cyclooxygenases |
Q38095148 | Overview and assessment of risk factors for pulmonary embolism |
Q36842832 | Perioperative management of patients on chronic antithrombotic therapy |
Q33431611 | Platelet reactivity in patients with venous thrombosis who use rosuvastatin: a randomized controlled clinical trial |
Q57172953 | Polymorphisms in PARK2 and MRPL37 are associated with higher risk of recurrent venous thromboembolism in a sex-specific manner |
Q40989421 | Portomesenteric venous thrombosis as a rare cause of acute abdomen in a young patient: What should be the process of diagnosis and management? |
Q38214962 | Predicting recurrent venous thromboembolism in cancer: is it possible? |
Q92905420 | Predicting the risk of recurrent venous thrombosis: What the future might bring |
Q26865059 | Predicting the risk of venous thromboembolism recurrence |
Q34512379 | Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study |
Q95560997 | Preparation, characterization and in vitro thrombolytic activity of a novel streptokinase foam |
Q41458663 | Prevalence of Hereditary Thrombophilia in Patients Older Than 75 Years With Venous Thromboembolism Referred for Thrombophilia Screening |
Q36527065 | Prothrombotic gene variants as risk factors of acute myocardial infarction in young women |
Q38001827 | Pulmonary embolism and deep vein thrombosis |
Q64228949 | Re-Examining Genetic Screening and Oral Contraceptives: A Patient-Centered Review |
Q33734478 | Recurrent Deep Vein Thrombosis After the First Venous Thromboembolism Event: A Single-Institution Experience. |
Q64115907 | Recurrent venous thromboembolism patients form clots with lower elastic modulus than those formed by patients with non-recurrent disease |
Q50660439 | Residual Vein Thrombosis Echogenicity Is Associated to the Risk of DVT Recurrence: A Cohort Study. |
Q83725478 | Risk assessment for recurrent venous thrombosis |
Q95474827 | Risk assessment for recurrent venous thrombosis |
Q95474835 | Risk assessment for recurrent venous thrombosis |
Q57183433 | Risk factors for post-thrombotic syndrome in patients with deep vein thrombosis: from the COMMAND VTE registry |
Q64905654 | Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction. |
Q30889099 | Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data |
Q92681540 | Risk prediction of recurrent venous thrombosis; where are we now and what can we add? |
Q40499885 | Role of family history of venous thromboembolism and thrombophilia as predictors of recurrence: a prospective follow-up study |
Q36735715 | Role of genetic changes in the progression of cardiovascular diseases |
Q24197581 | Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism |
Q47304199 | Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism. |
Q34525565 | Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. |
Q36032737 | Taller women are at greater risk of recurrent venous thromboembolism: the Iowa Women's Health Study |
Q61815014 | Testosterone Therapy, Thrombophilia, Venous Thromboembolism, and Thrombotic Events |
Q36688746 | The Frequency of Some Thrombophilic Mutations in Eastern Turkey |
Q36445585 | The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs |
Q28067893 | The epidemiology of venous thromboembolism |
Q36987388 | The impact of the DoH Commissioning for Quality and Innovation incentive on the success of venous thromboembolism risk assessment in hospitalised patients. A single institution experience in a quality outcome improvement over a 4-year cycle |
Q51785468 | The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study. |
Q38250865 | The real value of thrombophilia markers in identifying patients at high risk of venous thromboembolism |
Q40993089 | Thrombomodulin gene c.1418C>T polymorphism and risk of recurrent venous thromboembolism |
Q30562555 | Unusual venous thrombosis in a 35-year-old man. |
Q91632100 | Venous thromboembolism in inflammatory bowel disease |
Q35825548 | Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism. |
Q82065973 | [Treatment of deep vein thrombosis and pulmonary embolism] |